Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa

Vaccine

Volumn 27, Issue 6, 2009, Pages 940-946

  Freeman, Esther E ^a   White, Richard G ^a   Bakker, Roel ^b   Orroth, Kate K ^a   Weiss, Helen A ^a   Buvé, Anne ^c   Hayes, Richard J ^a   Glynn, Judith R ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

HIV; HSV2; Primary prevention

Indexed keywords

HERPES SIMPLEX VACCINE; HERPES SIMPLEX VIRUS 2 VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AFRICA; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; VACCINATION; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; FEMALE; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 58249116909     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.074     Document Type: Article

References (49)

1. Mbopi Keou F.X., Gresenguet G., Mayaud P., Weiss H.A., Gopal R., Brown D.W., et al. Genital herpes simplex virus type 2 shedding is increased in HIV-infected women in Africa. AIDS 13 March (4) (1999) 536-537
2. Schacker T., Zeh J., Hu H.L., Hill E., and Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 178 December (6) (1998) 1616-1622
3. Corey L., Wald A., Celum C.L., and Quinn T.C. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 35 March (5) (2004) 435-445
4. McFarland W., Gwanzura L., Bassett M.T., Machekano R., Latif A.S., Ley C., et al. Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis 180 5 (1999) 1459-1465
5. Schacker T., Zeh J., Hu H., Shaughnessy M., and Corey L. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 186 December (12) (2002) 1718-1725
6. Schacker T., Ryncarz A.J., Goddard J., Diem K., Shaughnessy M., and Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280 July (1) (1998) 61-66
7. Mbopi-Keou F.X., Gresenguet G., Mayaud P., Weiss H.A., Gopal R., Matta M., et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 182 October (4) (2000) 1090-1096
8. Kilmarx P.H., Limpakarnjanarat K., Mastro T.D., Saisorn S., Kaewkungwal J., Korattana S., et al. HIV-1 seroconversion in a prospective study of female sex workers in northern Thailand: continued high incidence among brothel-based women. AIDS 12 October (14) (1998) 1889-1898
9. Celum C., Levine R., Weaver M., and Wald A. Genital herpes and human immunodeficiency virus: double trouble. Bull World Health Org 82 June (6) (2004) 447-453
10. Wald A., and Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185 January (1) (2002) 45-52
11. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., and Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20 January (1) (2006) 73-83
12. Cowan F.F., Pascoe S.J., Barlow K.L., Langhaug L.F., Jaffar S., Hargrove J.W., et al. Association of genital shedding of herpes simplex virus type 2 and HIV-1 among sex workers in rural Zimbabwe. AIDS 20 January (2) (2006) 261-267
13. Mbopi-Keou F.X., Legoff J., Gresenguet G., Si-Mohamed A., Matta M., Mayaud P., et al. Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women. J Acquir Immune Defic Syndr 33 June (2) (2003) 121-124
14. Baeten J.M., McClelland R.S., Corey L., Overbaugh J., Lavreys L., Richardson B.A., et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 189 April (8) (2004) 1466-1471
15. Watson-Jones D., Weiss H.A., Rusizoka M., Changalucha J., Baisley K., Mugeye K., et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 358 15 (2008) 1560-1571
16. Celum C., Wald A., Hughes J., Sanchez J., Reid S., Delany-Moretlwe S., et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371 9630 (2008) 2109-2119
17. Garnett G.P., Dubin G., Slaoui M., and Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 80 February (1) (2004) 24-29
18. Stanberry L.R. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 August (Suppl. 3) (2004) 161A-169A
19. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-d-adjuvant vaccine to prevent genital herpes. N Engl J Med 347 November (21) (2002) 1652-1661
20. Smith J.S., and Robinson N.J. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 186 October (Suppl. 1) (2002) S3-S28
21. Blower S., and Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis 39 November (Suppl. 5) (2004) S240-S247
22. Korenromp E.L., Bakker R., Gray R., Wawer M.J., Serwadda D., and Habbema J.D. The effect of HIV, behavioural change, and STD syndromic management on STD epidemiology in sub-Saharan Africa: simulations of Uganda. Sex Transm Infect 78 April (Suppl. 1) (2002) i55-i63
23. Freeman E., Orroth K., White R.G., Glynn J.R., Bakker R., Boily M.-C., et al. The proportion of new HIV infections attributable to HSV-2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. STI 83 (2007) i17-i24
24. Abu-Raddad L.J., Magaret A.S., Celum C., Wald A., Longini I.M.J., Self S.G., et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3 5 (2008) e2230
25. Korenromp E., Bakker R., De Vlas S., Robinson N., Hayes R., and Habbema J. Can behaviour change explain increases in the proportion of genital ulcers attributable to herpes in sub-Saharan Africa? A simulation modelling study. Sex Transm Dis 29 April (4) (2002) 228-238
26. White R.G., Freeman E.E., Orroth K.K., Bakker R., Weiss H., O'Farrell N., et al. Population-level effect of HSV-2 therapy on HIV incidence in sub-Saharan Africa. Sex Trans Inf 84 S2 (2008) 12-18
27. Orroth K.K., Freeman E., Bakker R., Buve A., Glynn J., Boily M.-C., et al. Understanding differences across the contrasting epidemics in East and West Africa: results from a simulation model of the Four Cities Study. STI 83 (2007) i5-i16
28. Van der Ploeg C.B.P., Van Vliet C., De Vlas S.J., Ndinya-Achola J.O., Fransen L., Van Oortmarssen G.J., et al. STDSIM: a microsimulation model for decision support in STD control. Interfaces 28 (1998) 84-100
29. Korenromp E.L., Van Vliet C., Bakker R., De Vlas S.J., and Habbema J.D.F. HIV spread and partnership reduction for different patterns of sexual behaviour-a study with the microsimulation model STDSIM. Math Popul Stud 8 2 (2000) 135-173
30. White R.G., Orroth K.K., Glynn J.R., Freeman E.E., Bakker R., Habbema J.D.F., et al. Treating curable sexually transmitted infections to prevent HIV in Africa: still an effective control strategy?. J Acquir Immune Defic Syndr 47 (2008) 346-353
31. Orroth K.K., White R.G., Korenromp E.L., Bakker R., Changalucha J., Habbema J.D., et al. Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: simulation results. Sex Transm Dis 33 September (9) (2006) 536-544
32. White R.G., Glynn J.R., Orroth K.K., Freeman E.E., Bakker R., Weiss H.A., et al. Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when?. AIDS 22 14 (2008) 1841-1850
33. Koelle D.M., Benedetti J., Langenberg A., and Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 116 6 (1992) 433-437
34. Benedetti J.K., Zeh J., and Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 131 July (1) (1999) 14-20
35. Wald A., Zeh J., Selke S., Ashley R.L., and Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. New Engl J Med 333 12 (1995) 770-775
36. Mertz G.J., Ashley R., Burke R.L., Benedetti J., Critchlow C., Jones C.C., et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis 161 April (4) (1990) 653-660
37. Corey L., Adams H.G., Brown Z.A., and Holmes K.K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 98 June (6) (1983) 958-972
38. Kim H.N., Wald A., Harris J., Almekinder J., Heitman C., and Corey L. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. Sex Transm Dis 35 February (2) (2008) 124-128
39. Corey L., Wald A., Patel R., Sacks S.L., Tyring S.K., Warren T., et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 350 January (1) (2004) 11-20
40. Hayes R.J., Schulz K.F., and Plummer F.A. The cofactor effect of genital ulcers on the per-exposure risk of HIV transmission in sub-Saharan Africa. J Trop Med Hyg 98 February (1) (1995) 1-8
41. Mark KE, Wald A, Magaret AS, Selke S, Olin LP, Huang M-L, et al. Rapid onset and clearance of genital HSV reactivations In Immunocompetent adults: the virus is usually 'on' ISSTDR; Seattle, International Society for Sexually Transmitted Diseases Research; 2007.
42. Auvert B., Buvé A., Ferry B., et al. Ecological and individual level analysis of risk factors for HIV infection in four urban populations in sub-Saharan Africa with different levels of HIV infection. AIDS 15 Suppl. 4 (2001) S15-S30
43. Freeman E. The role of herpes simplex virus type 2 in the spread and control of HIV in four sub-Saharan African cities (2006), London School of Hygiene and Tropical Medicine, London University, London
44. Todd J., Glynn J.R., Marston M., Lutalo T., Biraro S., Mwita W., et al. Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS 21 November (Suppl. 6) (2007) S55-63
45. Weiss H.A., Thomas S.L., Munabi S.K., and Hayes R.J. Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect. 82 April (2) (2006) 101-109 [discussion 10]
46. Gray R.H., Kigozi G., Serwadda D., Makumbi F., Watya S., Nalugoda F., et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369 February (9562) (2007) 657-666
47. Rottingen J.A., Cameron D.W., and Garnett G.P. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known?. Sex Transm Dis 28 10 (2001) 579-597
48. Gray R., and Wawer M. Reassessing the hypothesis on STI control for HIV prevention. Lancet 371 9630 (2008) 2064
49. Baggaley R.F., Garnett G.P., and Ferguson N.M. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 3 March (4) (2006) e124